Investigational drug · Phase 2
VH3810109
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for HIV Infections.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "VH3810109"
First trial start
2023
Aug 17, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VH3810109", any sponsor or status.
Conditions studied
As listed on its trial records.
- HIV Infections
Approved drugs for the same conditions: Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "VH3810109" as an intervention, largest first.
- A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)Pivotal-lookingActive, not recruiting
ViiV HealthcareGSK (GSK)
NCT05996471 · 185 participants · Start Aug 17, 2023 · Primary completion May 27, 2026
Drug: VH3810109; Cabotegravir and 2 more · For: HIV Infections
Sites: Birmingham, Alabama; Bakersfield, California; Los Angeles, California · 45 sites in all
- A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIVPivotal-lookingActive, not recruiting
ViiV HealthcareGSK (GSK)
NCT07053384 · 107 participants · Start Jul 10, 2025 · Primary completion Jan 22, 2027
Drug: VH3810109; Fostemsavir (FTR) and 1 more · For: HIV Infections
Sites: Bakersfield, California; San Diego, California; Ft. Pierce, Florida · 41 sites in all
ViiV HealthcareGSK (GSK)
NCT05291520 · 24 participants · Start Feb 23, 2022 · Primary completion Apr 10, 2023
Drug: VH3810109; rHuPH20 · For: HIV Infections
Sites: Austin, Texas
Newest research
PubMed records naming it or its code names, newest first.
- VH3810109 Efficacy, Safety, Pharmacokinetics, and Incidence of Antidrug Antibodies in Adults With HIV-1 Naive to Antiretroviral Therapy: BANNER Study Results.
Leone PA, Ferro A, Rolle CP, et al. · J Infect Dis 2025
- VH3810109 (N6LS) broadly neutralizing antibody safety, pharmacokinetics, and anti-drug antibody incidence in adults without HIV: phase 1 SPAN study results.
Leone PA, Losos J, Wannamaker P, et al. · Antimicrob Agents Chemother 2025
Also in development for HIV Infections
- rHuPH20Phase 35 trials
Bristol Myers Squibb · Melanoma, Relapsing-remitting Multiple Sclerosis, Clear Cell Renal Cell Carcinoma
- TeropavimabTAB, GS-5423Phase 33 trials
Gilead Sciences · HIV-1 Infection, HIV Infections, HIV-1-infection
- ZinlirvimabGS-2872, ZABPhase 33 trials
Gilead Sciences · HIV-1 Infection, HIV Infections, HIV-1-infection
- 2 NRTIsPhase 32 trials
Merck & Co. · Human Immunodeficiency Virus (HIV) Infection, Infection, Human Immunodeficiency Virus, HIV Infections
- ABC3TC STR, 3TC immediate releasePhase 32 trials
GSK · HIV Infections
- ARTPhase 32 trials
GSK · HIV Infections, HIV-1 Infection
- DTGPhase 32 trials
Jiangsu Aidea Pharmaceutical Group Co., Ltd. · Infection, Human Immunodeficiency Virus, HIV Infections
- BMS-663068Phase 31 trial
GSK · HIV Infections
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from GSK.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.